OTC Antitussive Menthol Chewing Gum Requires NDA Deviation – FDA
This article was originally published in The Tan Sheet
Executive Summary
A menthol-containing topical antitussive drug with chewing gum as a delivery form necessitates submission of an NDA deviation, FDA states
You may also be interested in...
Chewing Gum Acceptable Menthol Delivery Form, Petitioners Suggest
A chewing gum dosage vehicle could deliver 5 mg of menthol in a 20-minute period, similar to already-approved lozenges, according to a citizen petition filed with FDA May 25.
Pfizer Rid Mousse Pediculicide Approved Under "NDA Deviation"
FDA approved an "NDA Deviation" (21-043) for Pfizer's Maximum Strength Rid Mousse aerosolized foam lice treatment March 7. It is one of the first "NDA Deviations" to get the go-ahead from the agency; such an application is for a product that is comparable to products in a monograph but deviates in a significant way.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC